NCT03340506 2026-04-01Dabrafenib and/or Trametinib Rollover StudyNovartisPhase 4 Recruiting100 enrolled
NCT07504796 2026-04-01ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabNYU Langone HealthPhase 4 Not yet recruiting90 enrolled
NCT07459543 2026-03-09A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In IndiaBristol-Myers SquibbPhase 4 Not yet recruiting30 enrolled
NCT07426484 2026-02-23Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyDana-Farber Cancer InstitutePhase 4 Not yet recruiting80 enrolled